INTRODUCTION
Due to increased life expectancy and optimized medical treatments, there is a clear need for novel, innovative approaches in reconstructive urology. The aim of tissue engineering (TE) reconstruction is to improve the postoperative functional outcome using customized natural materials to support the regenerative aspect of the healing process. Key factors which are identified for an optimal biological material are proper scaffold construction and proper regeneration of the urothelium and smooth muscle layers [Drewa, 2015] . The engineered scaffold aims to replace the extracellular matrix (ECM), support cell growth and expansion, and provide a mechanical and functional structure to replace and incorporate the native tissue. For long-term success, the scaffold should be resorbable or autologous to prevent foreign body reactions (FBR) that could lead to scarring [Atala, 2012]. However, the ideal matrix has not yet been identified, and it remains questionable whether there is a matrix that is suitable for the reconstruction of the entire urinary tract.
Another important question in TE reconstruction is why we have not seen more materials in clinical practice. The possible answer is that the main problem is the Registry >100
GOALS
The composition of the ECM of human amniotic membrane (HAM) is similar to that of the basement membrane in the urinary tract. Today, HAM allografts are used for reconstruction in eye and oral surgery and as dressings in burn patients. Therefore, our main goal was to prove that amniotic tissue can be an appropriate scaffold for reconstructive techniques in the urinary tract. We aimed to develop a standardized and manufacturer-independent process for amnion graft preparation, ensuring sterilization while keeping the ECM intact. Moreover, we aimed to ensure that the grafts provide feasible materials for surgical practice. Having achieved these goals, we conducted in vivo experiments, and, finally, we investigated the possibility of transferring experimental results into clinical practice following the steps in the IDEAL-D framework.
Study I. The main purpose was to develop an in vitro approach for amnion preparation and to preserve ECM integrity. Different mono-and multilayer techniques were tested to achieve a perfect hold and processing of HAM.
Study II. We aimed to investigate the possibility of bladder and colon grafting and the immunogenicity of processed HAM xenografts in vivo. Histological analyses were performed to investigate the degradation of HAM and graft rejection and the ingrowths of surrounding tissue 7, 21 and 42 days after the implantation.
The goal of Study III was to translate the in vivo animal results into a clinical scenario. HAM allografts were used to treat human vesico-vaginal fistulas and a case of a chronic wound with an entero-cutaneous fistula. The patients were followed up in a registry for one year.
MATERIALS AND METHODS

In vitro and in vivo experiments
HAMs were obtained after elective Caesarean sections and informed consent from the patients. The amnion was detached from the chorion by mechanical traction, and the separated amniotic membranes were cut into 5x5 cm segments. The HAMs were fixed to a sterile silicon scaffold and frozen at -20°C for 24h until further use. (Pilot studies have shown that storage for up to six months does not cause degradation.) For further processing, the HAMs were thawed, sterilized in a 0.25% peracetic acidalcohol mixture and incubated for 2h. Various HAM layers were tested to achieve the best processing with the possibility to cut and suture.
Fresh HAM (fHAM) and processed (frozen, sterilized and dried) HAM (pHAM) samples were sectioned and stained with H&E according to standard protocols for the in vitro studies. The tissues were stained for Ki-67 using rabbit primary antibodies to determine cell proliferation.
48 male Sprague Dawley rats were used at the Institute for Surgical Research of the University of Szeged, Hungary (license number V./146/2013) for the in vivo experiments. The rats were anaesthetized with 40 mg/kg 10% ketamine, a midline laparotomy was performed, and the bladder pressure was evaluated with the cystometric method developed by Lundbeck et al. Subsequently, a defined 0.5 cm lesion was cut at the bladder dome. In the second group, a defined 0.5 cm length of the caecum wall was resected. In the treated amnion groups (bladder n=18 and colon n=18), a multilayer amnion patch was trimmed to cover the defect size (10x10 mm) and was fixed to the bladder or colon wall with 6-0 Monocryl single sutures at 3-4 points. Additional human fibrin glue was used to seal the lesion. In the first control group (B1, n=6 and C1, n=6), the defect was closed with a single Monocryl 6-0 running suture and fibrin glue. In the second control group (B2, n=3 and C2, n=3), the amnion graft was sutured to the bladder or colon wall without a prior lesion. The animals were sacrificed at one week (Ba and Ca, n=10; B1 and C1, n=4; B2 and C2, n=2) , three weeks (Ba and Ca, n=12; B1 and C1, n=4; B2 and C2, n=2) and six weeks (Ba and Ca, n=10; B1 and C1, n=4; B2 and C2, n=2) to a heat-induced antigen retrieval (citrate buffer, pH 6.0), followed by 3% hydrogen peroxide and avidin-biotin blocking. Prior to incubation with the primary antiserum, sections were incubated with a PBS blocking solution containing 10% normal horse serum, 0.1% bovine serum albumin, 0.05% thimerosal, 0.01% NaN3 and 1% Triton X-100. Primary and secondary antisera were diluted in a blocking solution without
Triton X-100. Sections were incubated overnight with the primary antibody and immunostained with the streptavidin-biotin peroxidase method, followed by a diaminobenzidine (DAB) chromogen solution. Finally, sections were counterstained with haematoxylin. Negative controls were incubated in a blocking solution without primary antibodies. Digital images of H&E and α-actin were used for the evaluation of smooth muscle content within the reconstructed wall. Pictures were taken using a Zeiss Axiophot microscope equipped with an Olympus DP70 digital camera at 4x magnification. HAM thickness was measured (in µm), with particular attention paid to the transition zone between the amnion graft and the normal bladder or colon wall.
A semiquantitative score from 0 to 3 for inflammation and from 0 to 2 for vascularization was used. Inflammation of the implant region was scored by counting lymphocytes in ten fields of 0.25 mm 2 in three observer-randomized H&E-stained slides (0= <5% cells/field; 1= 5-25%; 2= 25-50%; 3= >50%; 200x magnification). A similar score was used for vascularization (0= 0 vessels/mm², 1= 1-3 v/mm²; 2= >3v/mm²; 200x magnification). Kidney and spleen specimens were analysed for signs of transplant rejection.
Clinical studies I.
A 64-year-old female was admitted to the Department of Urology, Lukas Hospital
Neuss, Germany, with sigma diverticulitis and a chronic vesico-vaginal fistula (VVF). She had a previous history of cervical cancer and radio-chemotherapy for anal cancer with complete remission. The VVF persisted after multiple abdominal operations, and the patient suffered from permanent incontinence and a local skin infection. After a recovery period of three months, we re-evaluated the patient with cystography, cystoscopy, ureteropyelography and a vaginal examination. A complex vesico-vaginal fistula of 1.5 cm was detected at the apical anterior vaginal wall leading to the bladder base. Additionally, scarring of the vagina and distal ureters was found, and the patient suffered from a persistent MRSA colonization of the urine. Due to the complex situation, it was decided that an individualized treatment would be used with off-label use of HAM. Prior to surgery, three layers of HAM were fixed with a 4-0 Monocryl suture, and a multilayer HAM of 4 cm was used as a graft to close the defect at the edges of the normal bladder wall.
II. An 83-year-old female underwent a radical cystectomy with a cutaneous ureterostomy for locally invasive bladder cancer at the Department of Urology, Lukas Hospital Neuss, Germany. Two weeks after surgery, she was admitted again with a severe infection of the laparotomy wound. A wide resection of subcutaneous tissue with vacuum sealing was necessary, followed by displacement plastic skin repair. Seven days later, the patient presented with a cutaneous fistula with purulent secretion and communication with a small bowel loop. Two layers of amnion dressing were applied weekly after cleaning and debridement for four weeks. The wound size was documented, and a biopsy at the wound margin was performed at week four.
Statistics
Data from different experimental groups were compared using the Mann-Whitney U test and the Kruskal-Wallis test. Data are presented as medians with ranges or means with standard deviation (SD). P values <0.05 were considered significant.
RESULTS
In vitro experiments
Processed pHAMs were compared with fresh tissues by histology using H&E staining. pHAM maintained tissue thickness and structural integrity on a comparable level with the amniotic layer of fresh tissue. However, neither fresh amnion nor pHAM displayed any positive staining for Ki-67. For the best hold, 4-0, 5-0 and 6-0
Monocryl sutures were used at 3-4 points to fix the HAM to the scaffold.
In vivo studies -bladder reconstruction with amnion xenografts
Two animals (11%) died in the treated group: one due to postoperative sepsis, No signs of severe inflammation were found in the abdominal cavity during reoperation. Meso-adhesions to the HAM graft were detected in most of the treated cases. HAM appeared as a thick, oedematous graft with inflammation running from the middle towards the transition zone of the bladder wall at day 7. At days 21 and 42, HAM was still well defined, albeit with reduced inflammation. Adhesions were present in some cases. Inflammation was less prominent in the control groups.
The xenotransplanted HAM graft covered the bladder wall and maintained its architecture at day 7. The lesions could be recognized as regions without smooth muscle cells but with abundant connective tissue and signs of inflammation.
Significant inflammation and an increased number of blood vessels were observed in the amnion and between the amnion and the adventitia of the bladder, resulting in an enlarged amnion. Infiltrated lymphocytes agglomerated mostly in the area bordering the HAM. At day 21, the amnion appeared less thick, and the inflammation was significantly diminished (p<0.05). New capillaries started to grow into the surrounding connective tissues, and scattered smooth muscle cells emerged in the area of the lesion. In the control groups, signs of inflammation had mostly disappeared. At day 42, it became more difficult to discern the region of the lesion, where the amnion formed a thinner layer on the bladder wall with no signs of degradation. Inflammation was markedly reduced in the amnion and in the zone between the amnion and the bladder wall (p<0.05). The number of large vessels in the amnion appeared to be reduced and periamniotic vascularization increased, but these results were not significant. Connective tissue, bundles and thin muscle layers were found in abundance in all groups. Smooth muscle regeneration occurred more rapidly in the amnion group, although the difference in the regeneration compared to the control group with the suture of the lesion was not significant (p<0.05).
In vivo colon reconstruction with amnion xenograft
During reoperation, the HAM appeared as a thick oedematous graft with signs of inflammation, but severe inflammation was not found in the abdominal cavity. The inflammation was less severe in the control groups. Strong adhesions of the HAM graft to the small bowel and abdominal wall that withstood tractions were detected in most of the treated cases. At day 7, a higher adhesion score with a larger coverage area was found in the amnion group (1.8±0.45) vs. group C1 (0.5±0.7) (p<0.05).
However, similar adhesion scores were present in groups C1 and C2. At day 21, the adhesion score was higher in the amnion group (1.8±0.84) vs. group C1 (1±0) (p=0.178), but the difference was statistically not significant. HAM could not be identified and in some cases could not be detected at day 42. The adhesions increased in the amnion group vs. groups C1 and C2 (p=0.052).
At day 7, strong inflammation with abundantly increased numbers of lymphocytes and blood vessels was observed in the amnion layers and between the amnion and the submucosa of the colon, which resulted in an enlarged amnion. A lower-level, but still strong inflammation was found in control groups C1 and C2. HAM thickness was reduced, and the inflammation was significantly decreased (p<0.05) at days 21 and 42. Connective tissue bundles and scattered smooth muscle cells appeared in the area of the lesion. In control group C1, signs of inflammation (the presence of lymphocytes) had mostly disappeared, and there were also no clear signs of regeneration of smooth cells in the lesion region. At day 42, it became more difficult to verify the presence of the amnion in the treated group, and the different layers of the amnion could no longer be distinguished. The amnion, which was significantly reduced in thickness, formed a thinner layer on the colon wall. In the control group without lesions (C2), the amnion was completely degraded and could no longer be detected. Inflammation was markedly reduced in the amnion and in the zone between the amnion and the colon wall, but it was still significantly higher compared to control group C1 (p<0.05). Despite the presence of scattered smooth muscle cells and bundles, it was difficult to measure if there was a clear regeneration of smooth muscle compared to control group C1.
No macroscopic signs of rejection were found in the kidney and spleen specimens.
However, four out of six animals in the treated group showed an affected kidney at day 21. To rule out an obstruction or increased bladder pressure as the cause of these findings, we compared the results with the colon study, and the same results were demonstrated. The changes were subtle with slightly enlarged tubuli and a slightly enlarged urinary space, the glomeruli appeared denser, and no presence of immune cells or other signs of transplant rejection were found. At day 42, the kidneys of two out of five animals were still slightly affected, whereas no such changes were detected in the controls. On the whole, this suggests that a transient, subtle transplant glomerulitis was present in the rats with HAM grafts.
Clinical cases -vesico-vaginal fistula
Seven days after surgery, a cystography was performed, and no leakage was present.
In the next three months, re-evaluations with cystography, cystoscopy and a vaginal examination were performed, no recurrent fistula was found, and full recovery of the vaginal epithelium was present. The ureter stents were internalized, and the patient was able to micturate without incontinence. The bladder capacity was restored to a volume of 250 ml. No severe complications and no signs of graft rejection were observed over a period of six months. The MRSA colonization in the urine was successfully eradicated. However, during the follow-up at ten months, the patient reported vaginal urine leakage again and a recurrent fistula was observed at the margin of the amnion graft.
Treatment of an entero-cutaneous fistula
The wound size was 3x2x1 cm when the HAM was applied. After two weeks, the secretion stopped, and the ulcer was reduced by 20% and then healed after eight weeks with four applications of HAM. The healing was complete after six-month and nine-month follow-ups. Histological analysis showed re-epithelialization and recovery of muscle cells four weeks after the treatment. The HAM did not degrade and could still be detected as a smooth layer on the surface. Moderate inflammation was present, but signs of graft rejection were not observed. where the caecum was covered with a 10 mm amnion wrap, the leakage rate was as high as 25% after seven days in the standard anastomosis group vs. 0% in the amnion group [Uludag, 2009]. Unlike in our model, the authors reported a high dehiscence rate of 40-50% in the control group with standard anastomosis. The difference is probably due to the different experimental design. In our study, no signs of dehiscence were detected in the control group with the suture of a small bowel wall defect. However, the increased initial inflammation and adhesions in the amnion group appear to be a sign of insufficient bowel sealing with an amnion graft. This notion is supported by the finding that one case of postoperative peritonitis and sepsis was detected in the HAM group.
DISCUSSION
In conclusion, we suggest that HAMs alone are not suitable barriers to preventing adhesions and inflammation, and therefore this technique is not useful or superior to a standard suture for the reconstruction of the bowel wall in a xenograft model.
However, the anastomosis-protective potential of HAM use in a high-risk situation (e.g. peritonitis model) needs to be evaluated further. Other limitations of our study were the rather small size of the grafts (10x10 mm), the short follow-up, the small sample size and the xenograft model itself. Nevertheless, it should be added that a smaller number of elements was purposefully planned as is the case with proof-ofprinciple studies.
The xenograft animal model and the IDEAL recommendations
Rodents are employed as standard cost-effective models for most preclinical trials. This notion is supported by the fact that HAMs in human patients did not induce inflammation and graft rejection; the grafts were well-tolerated without side-effects.
Nevertheless, future studies should test different HAM-grafting techniques in animal models of peritonitis and fistulas to simulate the outcome in humans. We were the first to report on the successful treatment of an entero-cutaneous fistula and infected wound with HAM. In our case, the external dressings were changed every two days due to the initial infection of the wound.
HAM-assisted repair of a vesico-vaginal fistula
HAM is simple to use and makes it possible to cover larger and irregular wound areas as well as deep tunnelling wounds. Future studies in larger numbers of patients with infected wounds should be conducted, and inclusion of amnion dressings in the algorithm of secondary wound care should also be evaluated. However, the results suggest that HAM can be a cost-effective treatment for chronic wounds and can reduce hospitalization time.
The project with regard to the IDEAL-D recommendations
The protection of intellectual property should be regulated by the authorities at the 
SUMMARY OF THE NEW FINDINGS
The development of this surgical device (i.e. the use of HAM in reconstructive urology) strictly followed the IDEAL-D recommendations at every step to ensure comparability and transparency.
1.
A sterilization process was developed for HAM, and a method was designed to achieve stability and better handling during surgery. Several layers of HAM were attached to a silicon scaffold, and histological evidence was provided that the ECM structure and collagen composition were preserved during the processing method. 
5.
We demonstrated that an entero-cutaneous fistula with an infected wound can be successfully treated with several HAM dressings. The use of HAM allowed for the coverage of large and irregular surface areas and deep tunnelling wounds. This suggests that HAM can be a useful, potential scaffold for reconstruction surgeries.
